Shanghai and Hong Kong, PRC, August 24, 2026
Antengene Corporation Limited has reported its first-ever profitable period, alongside continued clinical and technology advances across its oncology and autoimmune disease pipeline. For the first half of 2026, the commercial-stage biotechnology company recorded RMB 513 million in revenue, representing an 864.5% year-over-year increase, while profit for the period reached RMB 216 million. The company said its financial performance was supported by commercial revenue and global licensing partnerships, while its research and development programs continued to expand across antibody-drug conjugates (ADCs), T-cell engagers (TCEs), bispecific therapies and other novel modalities.
ATG-022 Advances in CLDN18.2-Positive Cancer
A major focus of Antengene’s clinical pipeline is ATG-022, a CLDN18.2-targeted antibody-drug conjugate being developed for gastric and gastroesophageal junction cancers as well as other CLDN18.2-positive solid tumors. The company reported encouraging Phase II CLINCH study results as of June 26, 2026. Among patients with moderate-to-high CLDN18.2 expression, the 2.4 mg/kg cohort achieved an objective response rate (ORR) of 42.4% and a disease control rate (DCR) of 90.9%, with median overall survival of 12.85 months. In the 1.8 mg/kg cohort, ORR reached 46.7%, while DCR was 86.7%; median overall survival had not yet been reached after a median follow-up of 14.03 months. The company also reported responses among patients with low or ultra-low CLDN18.2 expression, supporting further investigation of the therapy across different expression levels. Antengene is pursuing three complementary development pathways for ATG-022. The pivotal Phase III CLINCH-3 study is evaluating ATG-022 monotherapy in third-line-or-later gastric or gastroesophageal junction cancer among patients with CLDN18.2 IHC 2+ expression of at least 20%. Meanwhile, the CLINCH-2 study is evaluating ATG-022 in combination with chemotherapy and an anti-PD-1 therapy in the first-line setting, targeting patients with CLDN18.2 IHC 1+ expression of at least 1%. A basket study is also exploring the candidate in other CLDN18.2-positive solid tumors.
New TCE Platforms Expand Drug Discovery
Antengene is also expanding its T-cell engager technology beyond its established AnTenGager® platform. The company has introduced TriGager™, a next-generation logic-gated tri-specific TCE platform designed to support different molecular formats, including AND-Gate, True AND-Gate and OR-Gate approaches. These designs are intended to improve target selectivity by requiring specific antigen combinations or recognizing alternative target patterns, potentially addressing challenges associated with heterogeneous disease biology and on-target, off-tumor toxicity. The company’s AnTenGager® platform uses a “2+1” bivalent binding format, steric hindrance masking and proprietary CD3 sequences designed to balance activity and safety. Antengene has already advanced multiple candidates from the platform, including ATG-201, a CD19 × CD3 TCE partnered globally with UCB, and ATG-106, a CDH6 × CD3 TCE licensed to K2 Therapeutics. The ATG-201 agreement generated a USD 60 million upfront payment, while ATG-106 carries approximately USD 20 million in aggregate upfront and near-term consideration, alongside potential future milestones and royalties.
Advertisement
AI and Next-Generation Therapeutics Strengthen Pipeline
Antengene is integrating artificial intelligence into its R&D engine by combining multi-omics analysis with internally generated protein datasets. According to the company, its AI platform is being used to identify novel targets and target combinations, support molecular design and improve antibody developability. The approach has contributed to the nomination of ATG-115, a T-cell engager targeting a novel tumor-associated antigen identified through AI-enabled research. Beyond ATG-022 and its TCE programs, Antengene is progressing ATG-125, a B7-H3 × PD-L1 bispecific ADC, with an IND submission planned for the first quarter of 2027. The company is also developing ATG-207, an αCD3-TGF-β bifunctional fusion protein for T-cell-mediated autoimmune diseases, alongside additional TCE candidates targeting solid tumors and hematologic malignancies.Financially, Antengene ended the reporting period with RMB 765 million in cash and bank balances and subsequently received approximately RMB 195 million in license revenue from UCB in July 2026. The company said its stronger financial position will support continued investment in clinical development, innovative drug discovery and global partnerships.
Source: Antengene press relese
